bio.org/CEO • #BIOCEO16

February 13-14, 2017 • The Waldorf Astoria New York

bio.org/CEO • #BIOCEO17

CEO INVESTORCONFERENCE

bio.org/CEO2 bio.org/CEO2

WHY ATTEND?• EXPERIENCE the largest, unbiased forum where institutional

investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry.

• HEAR Washington’s perspective on how the Trump Administration will address ACA, CMS and PDUFA VI.

• EVALUATE fresh investment opportunities including compatible, complementary and competitive companies.

• LEARN about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.

• ATTEND fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2017.

• GAIN ACCESS to BIO’s One-on-One Partnering system for scouting potential investments and deal partners, optimizing your time at the event.

• HEAR presentations from more than 175 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.

• GET THE PULSE of the current and proposed investment trends in biotechnology.

• NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions.

CEO INVESTORCONFERENCE

Now in its 19th year, the BIO

CEO & Investor Conference

is one of the largest investor

conferences focused on

established and emerging

publicly traded and select

private biotech companies.

2 bio.org/CEO

3#BIOCEO17

CEO INVESTORCONFERENCE

3#BIOCEO17

Fireside Chats feature

candid discussions between

biopharma executives, Wall

Street analysts, and other

high-level industry experts.

Hear about recent company

successes, what keeps the

C-suite up at night, and

where the industry’s leading

companies are headed in 2017.

Giovanni Caforio, MDChief Executive Officer, Bristol-Myers Squibb

Tony Coles, MDChairman and Chief Executive Officer, Yumanity Therapeutics

Jeffrey D. MarrazzoCo-Founder and Chief Executive Officer, Spark Therapeutics

Lynn Seely, MDChief Executive Officer, Myovant Sciences

J. Joseph Kim, PhDPresident and Chief Executive Officer, Inovio Pharmaceuticals

2017 FIRESIDE CHAT SPEAKERS

bio.org/CEO4

2017 AGENDAAPPLYING MICROBIOME RESEARCH TO THERAPEUTICSMonday • February 13, 2017 • 9:00 am – 9:55 am

New discoveries are finding links that extend significantly beyond the gut microbiome and intestinal disorders into a range of bodily systems including the immune and nervous systems. Major biopharma companies have engaged in significant deals that envision treatments to commercialize from this research and leading companies are pushing forward on clinical trials. This session will outline the microbiome influenced therapies most likely to create major effects for patients.

MODERATOR: C. Simone Fishburn, PhD, Editor, BioCentury Innovations

SPEAKERS Pierre Belichard, PharmD, PhD, Chief Executive Officer, Enterome Mark Bodmer, PhD, Chief Scientific Officer, Evelo Biosciences Aoife M. Brennan, MD, Chief Medical Officer, SynlogicNick Conley, PhD, Board of Directors, Co-founder & Chief Executive Officer, EpiBiome Jeffrey Riley, Chief Executive Officer, President and Director, Synthetic BiologicsNikola Trbovic, PhD, Director R&D Technology Strategy, Worldwide Research & Development, Pfizer Inc.

FIRESIDE CHAT WITH J. JOSEPH KIM, PHD President and Chief Executive Officer, Inovio Pharmaceuticals

Monday • February 13, 2017 • 10:00 am – 10:55 am

MODERATOR Phyllis A. Arthur, Managing Director, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization

CAR-T, TILS, AND BISPECIFICS: IMMUNO-ONCOLOGY CHALLENGES AND OPPORTUNITIESMonday • February 13, 2017 • 11:00 am – 11:55 am

The maturation of new cancer treatment technologies has produced a mix of highly positive patient outcomes and some serious clinical holds, while investments for manufacturing and commercialization continue to accelerate. This session will dive into the assumptions underlying the most aggressive approaches and the ways of reducing the risks of failure along the way to delivering immuno-oncology’s promise to patients broadly.

MODERATOR: Michael King, Managing Director and Senior Research Analyst, JMP Securities

SPEAKERS Joseph Pearlberg, MD, Vice President Clinical Development, Infinity Pharmaceuticals, Inc.Jeffrey Wolf, Chief Executive Officer, Heat Biologics Anton Xavier, Senior Scientist, Pfizer Inc.Jerome Zeldis, MD, PhD, Chief Medical Officer and President of Clinical Development, Sorrento Therapeutics

NEXT GENERATION PAIN CONTROL: BEYOND OPIOIDSMonday • February 13, 2017 • 1:30 pm – 2:25 pm

The scourge of rising addiction and heroin overdoses has been associated with the growth in usage of important, opioid-based, prescription pain treatments. New approaches to pain control are looking at different biological mechanisms and methodologies for improving patients’ lives with lower risks of ill effects or addiction. This session will speak with experts developing therapeutic innovations that do not rely on opioid-based drugs and can provide doctors additional alternatives for helping patients.

MODERATOR: Corey Davis, PhD, Managing Director, Senior Healthcare Analyst, H.C. Wainwright & Co., LLC

SPEAKERS Gail Cawkwell, MD, Chief Medical Officer, Purdue Pharma L.P.Derek Chalmers, PhD, DSc, Chief Executive Officer, President, and Director, Cara Therapeutics

Russell Herndon, President and Chief Executive Officer, Hydra BiosciencesJeffrey B. Kindler, Chief Executive Officer, Centrexion Therapeutics

FIRESIDE CHAT WITH TONY COLES, MD Chairman and Chief Executive Officer, Yumanity Therapeutics

Monday • February 13, 2017 • 2:30 pm – 3:25 pm

MODERATOR Ian Woo, Managing Director, Lazard

IPOS AND BEYOND: TAPPING INTO THE PUBLIC MARKET’S CAPITALMonday • February 13, 2017 • 3:30 pm – 4:25 pm

As biotech IPO activity has cooled from its 2015 peak, companies are more deliberately weighing reverse mergers and other alternatives to benefiting from the capital in public markets. With post-election market uncertainty, does the IPO market for 2017 seek to rise, fall, or stay level? What markers should CEOs watch for to gauge their timing and choices?

5#BIOCEO17

CEO INVESTORCONFERENCE

This session will feature experienced voices for explaining the practical techniques for getting into public markets and what investors are expecting to see in order to win their support.

MODERATOR Stephen B. Thau, Partner, Morrison & Foerster LLP

SPEAKERS James Cappuccio, Managing Director, Investment Banking, H.C. Wainwright & Co., LLC

Brian Hagerty, Senior Director, Head of Healthcare Capital Markets, New York Stock ExchangeDouglas E. Onsi, Chief Financial Officer, Leap Therapeutics, Inc.Sapna Srivastava, PhD, former Chief Financial Officer and Chief Strategy Officer, Intellia TherapeuticsNassim Usman, PhD, President and Chief Executive Officer, Catalyst Biosciences

FIRESIDE CHAT WITH LYNN SEELY, MD President and Chief Executive Officer, Myovant Sciences

Monday • February 13, 2017 • 4:30 pm – 5:25 pm

MODERATOR K.C. Stone, Managing Director, Head of Healthcare Investment Banking, BTIG

LIVING WITH BIOSIMILARS: STRATEGY FORMULATION AND LESSONS FROM OTHER MARKETSTuesday • February 14, 2017 • 9:00 am – 9:55 am

As biosimilar medicine options begin to roll-out in the United States, the regulatory and legal uncertainties are also starting to shrink below the market adoption uncertainties. As some innovator companies also pursue biosimilar development, and others seek to compete, there are opportunities to learn from jurisdictions that have allowed biosimilar medicines for longer periods, such as Japan and Europe regarding the reactions of doctors and payers. This session will feature executives from innovator companies explaining how they evaluate biosimilars within their pipelines, plus those with expertise on understanding the economic effects seen when biosimilars launch within a market.

MODERATOR Elizabeth Krutoholow, Senior Analyst, Bloomberg Intelligence

SPEAKERS Jennifer Alltoft, Head of Global Biosimilars, Pfizer, Inc.Patrick K. Lucy, Interim Chief Executive Officer, Pfenex

EMBEDDING DIVERSITY INTO BOARD AND EXECUTIVE TEAM RECRUITMENTTuesday • February 14, 2017 • 10:00 am – 10:55 am

The biopharma industry has seen enormous growth in recent years of the number of start-ups and IPOs, with hundreds of new executive team and board member positions being filled. However, the inclusion of underrepresented groups in these influential positions has failed to keep pace with the growth of biopharma companies and too often the decision-makers fail to reflect the employee bases they lead or patient populations they serve. This session will focus on practical approaches and successful examples to improve the diversity of leadership recruitment efforts and better align organizations with the full measure of talented people available.

MODERATOR Julie L. Gerberding, MD, MPH, Executive Vice President & Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health, Merck

SPEAKERS Colleen Cuffaro, PhD, Principal, Canaan Partners Faith L. Charles, Partner, Chair, Life Sciences, Thompson Hine LLP/ Chair, Women in Bio—Metro New YorkLinda S. Grais, MD, President and Chief Executive Officer, Ocera Therapeutics, Inc.Paul J. Hastings, Chairman and Chief Executive Officer, OncoMed Pharmaceuticals Stephen M. Ritoch, Chairman of the Board and Chief Executive Officer, Blaise GroupFaith

FIRESIDE CHAT WITH JEFFREY D. MARRAZZO, Co-Founder and Chief Executive Officer, Spark Therapeutics

Tuesday • February 14, 2017 • 11:00 am – 11:55 am

MODERATOR Erin McCallister, Senior Editor, BioCentury Publications

POLICY OUTLOOK—ACA, CMS, PDUFA VI AND THE TRUMP ADMINISTRATIONTuesday • February 14, 2017 • 12:30 pm – 1:25 pm

From a healthcare policy point of view, 2017 has the potential of being the most dramatic since the initial introduction of the Affordable Care Act. The new Trump Administration has suggested an interest in making wholesale changes in how medicines are regulated and paid for by the U.S. government. PDUFA will expire later this year if its planned replacement is not passed in a timely fashion, greatly complicating companies’ drug development strategies and budgets. This session will share the latest details on what policies the Trump Administration and Congress are pursuing that would support or upend the assumptions that biopharma executives and investors have built into their financial models.

bio.org/CEO6

MODERATOR Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research

SPEAKERS Alex M. Azar II, Chairman, Seraphim Strategies, LLC; former President, Lilly USA, LLC (2012-2017); former Deputy Secretary, U.S. Department of Health and Human Services (2005-2007)Jeanne Haggerty, Senior Vice President, Federal Government Relations, Biotechnology Innovation Organization (BIO) Jonathan Leff, Partner, Deerfield Management; Chairman, Deerfield InstituteBrian Rye, Senior Healthcare Policy Analyst, Bloomberg Intelligence

CRAFTING NEW APPROACHES TO VALUE-BASED THERAPY PAYMENT MODELS: STARTING WITH GENE THERAPIESTuesday • February 14, 2017 • 1:30 pm – 2:25 pm

Both innovator companies and payers of medicines have expressed a willingness to look beyond the “fee per pill” model to attributing value to the effects on patients’ health instead. The challenge of reimbursing for curative therapies versus lifelong treatments of chronic conditions presents a special challenge, but one that may shine a light on value-based approaches generally. This session will explore with the innovators making progress on gene therapies how they are envisioning the reimbursement model in ways that all stakeholders might appreciate, including doctors’, patients’, and payers’ perspectives.

MODERATOR Ted Haack, Owner, Managing Partner, Haack & Associates

SPEAKERS John Glasspool, (formerly Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta US, Shire)Roger Longman, Chief Executive Officer, Real EndpointsSandy Macrae, MB, ChB, PhD, President and Chief Executive Officer, Sangamo Biosciences, Inc.

DESIGNING CLINICAL TRIALS IN A 21ST CENTURY CURES PARADIGMTuesday • February 14, 2017 • 2:30 pm – 3:25 pm

The passage by Congress of the 21st Century Cures Act in late 2016 has opened up new opportunities and expectations for the design of clinical trials that the FDA will consider for regulatory review. Real world evidence and the stronger inclusion of patient perspectives on endpoints are two examples of the shifts that will impact therapy development. This session will explain the advantages and complications that drug developers and investors should be aware of as the Cures Act gets implemented.

MODERATOR Wade Ackerman, Partner, Covington & Burling LLP

SPEAKERS Jeff Allen, PhD, President & Chief Executive Officer, Friends of Cancer ResearchGregory W. Daniel, PhD, MPH, RPh, Deputy Director, Duke-Margolis Center for Health Policy Steven Kaminsky, PhD, Chief Science Officer, Rettsyndrome.org Christopher U. Missling, PhD, President and Chief Executive Officer, Anavex Life Sciences Corp.Raghuram Selvaraju, PhD, Managing Director, Senior Healthcare Analyst, Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC

FIRESIDE CHAT WITH GIOVANNI CAFORIO, MD Chief Executive Officer, Bristol-Myers Squibb

Tuesday • February 14, 2017 • 3:30 pm – 4:25 pm

MODERATOR Stephen Sands, Vice Chairman Investment Banking and Chairman Global Healthcare Group, Lazard

MARKET OUTLOOK—POST-INAUGURATION SCENARIOS FOR M&ATuesday • February 14, 2017 • 4:30 pm – 5:30 pm

While the past year has seen a fading in the IPO market, the volume of deal flow and valuations for M&A remain high. Many of the largest industry members have strong cash positions, and most analysts continue to expect pipeline enhancement via acquisition. As political forecasts suggest high potential for tax reform and other changes in how international deals might be reviewed, there are multiple ways 2017 could be a great year or a terrible year for biopharma M&A. This session will talk through the likely and extreme scenarios, as well as provide insight on what signs to watch for from Washington and Wall St. along the way.

MODERATOR Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence

SPEAKERS Adam H. Golden, Partner, Head of Corporate Practice Group—New York, Hogan Lovells

Ellen Lubman, Vice President, External Science & Innovation, Allergan PLC

Michael A. Margolis, RPh, Head of Healthcare Investment Banking, ROTH Capital Partners

Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital

Matthew Roden, PhD, Vice President and Head of Strategic Corporate Development, Bristol-Myers Squibb

CLOSING RECEPTION AND CHAMPAGNE TOASTTuesday • February 14, 2017 • 5:30 pm – 6:30 pm

7#BIOCEO17

CEO INVESTORCONFERENCE

2017 PRESENTING COMPANIESThe 2017 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, this meeting will once again feature a unique track of more than 30 high-caliber and established private company presentations.

CARDIOVASCULARAngionetics Inc.Capricor Therapeutics, Inc. (NASDAQ:

CAPR)Espero Pharmaceuticals, Inc.Karos PharmaceuticalsORIG3N, Inc.Resverlogix Corp. (TSX: RVX)CNS/NEUROLOGICALAcelRx Pharmaceuticals (NASDAQ:

ACRX) Alcobra (NASDAQ: ADHD)Axsome Therapeutics, Inc. (NASDAQ:

AXSM)Flex Pharma, Inc. (NASDAQ: FLKS)InVivo Therapeutics Corporation

(NASDAQ: NVIV)Neuralstem, Inc. (NASDAQ: CUR)NeuroRx, Inc.Neurotrope Bioscience (OTC: NTRP)Newron Pharmaceuticals SPA (SIX:

NWRN)ORYZON (BME: ORY)PHARNEXT (Alternext: ALPHA)Probiodrug AG (Euronext: PBD)RaNA TherapeuticsSerina Therapeutics, Inc.Tonix Pharmaceuticals Holding Corp.

(NASDAQ: TNXP)DERMATOLOGYExicure Inc.Foamix Pharmaceuticals (NASDAQ:

FOMX)Realm Therapeutics, Inc. (AIM: RLM)Sonoma Pharmaceuticals, Inc.

(NASDAQ: SNOA)DIAGNOSTICSBaebies, Inc.Biocept, Inc. (NASDAQ: BIOC)Chembio Diagnostics, Inc. (NASDAQ:

CEMI)Curetis N.V. (Euronext: CURE)Epinex Diagnostics, Inc.Exactus, Inc. (OTCQB: EXDI)Exosome Diagnostics, Inc.Interpace Diagnostics Group Inc.

(NASDAQ: IDXG)ITUS Corporation (NASDAQ: ITUS)LexaGene Holdings Inc. (TSX: LXG.V)Oncocyte (NYSE MKT: OCX)DRUG DELIVERYApricus Biosciences, Inc. (NASDAQ:

APRI)Corium International, Inc. (NASDAQ:

CORI)Oramed Pharmaceuticals (NASDAQ:

ORMP)pSivida Corp (NASDAQ: PSDV)GASTROINTESTINALAtlantic Healthcare plcConatus Pharmaceuticals Inc.

(NASDAQ: CNAT)Galectin Therapeutics (NASDAQ:

GALT)Innovate Biopharmaceuticals, Inc.RedHill Biopharma Ltd. (NASDAQ,

TASE: RDHL)

Sigmoid Pharma LimitedSynthetic Biologics, Inc (NYSE: SYNGENE/CEN THERAPYArgos Therapeutics, Inc (NASDAQ:

ARGS)Brainstorm cell Therapeutics

(NASDAQ: BCLI)Caladrius Biosciences, Inc. (NASDAQ:

CLBS)Cellular Biomedicine Group (NASDAQ:

CBMG)Editas Medicine (NASDAQ: EDIT)Heat Biologics (NASDAQ: HTBX)LogicBio Therapeutics IncOxford BioMedica Ltd (LSE: OXB)TxCell SA (Euronext: TXCL.PAIMMUNOLOGYBioNTech AGEnteromeOSE Immunotherapeutics (Euronext:

OSE)Sorrento Therapeutics (NASDAQ:

SRNEINFECTIOUS DISEASESAltimmune, Inc.American Gene Technologies

International Inc.AmpliPhi Biosciences Corp (NYSE

MKT: APHB)ContraVir Pharmaceuticals, Inc.

(NASDAQ: CTRV)EpiBiomeRebiotix, Inc.Spring Bank Pharmaceuticals, Inc.

(NASDAQ: SBPH)Vical Incorporated (NASDAQ: VICL)Noveome BiotherapeuticsINFLAMMATIONNoveome BiotherapeuticsMEDICAL DEVICESArch Therapeutics, Inc. (OTC: ARTH)CytoSorbents (NASDAQ: CTSO)METABOLIC DISEASEAptamiR Therapeutics, Inc.CohBar, Inc. (OTC: CBWR)Cymabay Therapeutics (NASDAQ:

CBAY)Orexigen Therapeutics, Inc. (NASDAQ:

OREX)SynlogicViking Therapeutics, Inc. (NASDAQ:

VKTX)MULTILINE GLOBAL BIOPHARMANOIGEL, LLCMULTIPLE THERAPEUTICSCitius Pharmaceuticals, Inc. (OTCQB:

CTXR)Fortress Biotech, Inc. (NASDAQ: FBIO)Mount Tam Biotechnologies (OTC:

MNTM)Symic Bio, Inc.TiGenix NV (Euronext: TIG)NON-PROFIT/ADVOCACY ORGANIZATIONJeffrey Modell FoundationMuscular Dystrophy Association

The Leukemia & Lymphoma SocietyTourette Association of America, Inc.ONCOLOGY2X Oncology, Inc4SC AG (FWB: VSC)Actinium Pharmaceuticals, Inc (NYSE

MKT: ATNM)Aeterna Zentaris (NASDAQ: AEZS)Apexian PharmaceuticalsAveo Oncology (NASDAQ: AVEO)BioLineRx Ltd. (NASDAQ, TASE: BLRX)Bio-Path Holdings, Inc. (NASDAQ:

BPTH)Calithera Biosciences (NASDAQ:

CALA)Cellectar Biosciences, Inc. (NASDAQ:

CLRB)ConcentRx, Inc.CTI BioPharma Corp. (NASDAQ: CTIC)Cue Biopharma IncCyclacel Pharmaceuticals, Inc.

(NASDAQ: CYCC, CYCCP)CytRx Corporation (NASDAQ: CYTR)Eleven Biotherapeutics (NASDAQ:

EBIO)epiSCIESSA Pharma Inc. (NASDAQ: EPIX,

TSX: EPI)Fennec Pharmaceuticals (TSX: FRX)Gradalis, Inc.Gritstone Oncology, IncHelix BioPharma Corp. (TSX: HBP)Immunicum AB (NASDAQ First North

Premier: IMMU)Immunovaccine (TSX: IMV, OTCQX:

IMMVF)Infinity Pharmaceuticals, Inc. (NASDAQ:

INFI)iTeos Therapeutics SALeap Therapeutics, Inc. (NASDAQ GS:

LPTX)MabVax Therapeutics Holdings, Inc.

(NASDAQ: MBVX)Mateon Therapeutics (OTCMKTS:

MATN)MetaStat, Inc. (OTCBB: MTST)Nanobiotix (Euronext: NANO)Novocure Limited (NASDAQ: NVCR)OncoMed Pharmaceuticals, Inc.

(NASDAQ: OMED)Onconova Therapeutics, Inc.

(NASDAQ: ONTX)OncoSec Medical Incorporated

(NASDAQ: ONCS)Opsona Therapeutics Ltd.Pieris Pharmaceuticals (NASDAQ:

PIRS)Progenics Pharmaceuticals,Inc.

(NASDAQ: PGNX)Salarius PharmaceuticalsScancell Holdings plc (LSE: SCLP.L)SciClone Pharmaceuticals Inc

(NASDAQ: SCLN)Sunesis Pharmaceuticals (NASDAQ:

SNSS)Sutro Biopharma Inc.Syros Pharmaceuticals (NASDAQ:

SYRS)Tarveda Therapeutics

TG Therapeutics (NASDAQ: TGTX)Vascular Biogenics LTD (NASDAQ:

VBLT)Vaxil Bio Ltd. (TSX-V: VXL)Verastem, Inc. (NASDAQ: VSTM)WILEX AG (FWB: WL6)Zenith Epigenetics Ltd.OPTHALMOLOGYInotek Pharmaceuticals Corporation

(NASDAQ: ITEK)Ocugen, Inc.Ocular Therapeutix, Inc. (NASDAQ:

OCUL)ThromboGenics NV (Euronext: THR.BRORPHAN/RARE DISEASEAlbireo Pharma Inc (NASDAQ: ALBO)Arcturus TherapeuticsBellerophon Therapeutics (NASDAQ:

BLPH)Catalyst Biosciences (NASDAQ: CBIO)Eiger BioPharmaceuticals, Inc

(NASDAQ: EIGR)EryDel SpAInMed Pharmaceuticals (CSE: IN,

OTCQB: IMLFF)ProMetic Life Sciences (TSX: PLI)Spotlight Innovation Inc. (OTCQB:

STLT)Summit Therapeutics (NASDAQ:

SMMT)OTHER22nd Century (NYSE: XXII)Akebia Therapeutics, Inc. (NASDAQ:

AKBA)Capnia, Inc. (NASDAQ: CAPN)PAIN MANAGEMENTCentrexion TherapeuticsKemPharm, Inc. (NASDAQ: KMPH)Proove Biosciences Inc.Relmada Therapeutics, Inc. (OTCQB:

RLMD)PLATFORM FOR THERAPEUTICSDimerix Ltd (ASX: DXB)RXi Pharmaceuticals Corporation

(NASDAQ: RXII)SmartZyme Biopharma Ltd.REGENERATIVE MEDICINEBioTime, Inc. (NYSE MKT: BTX)REPRODUCTIVE/SEXUAL HEALTHAgile Therapeutics, Inc (NASDAQ:

AGRX)Palatin Technologies, Inc.

(NYSE MKT: PTN)RESPIRATORYAradigm Corporation (NASDAQ: ARDM)RespireRx Pharmaceuticals Inc.

(OTCQB: RSPI)TOOLS/DRUG DEVELOPMENT SUPPORT TECHNOLOGYIonField Holdings LLC,

dba IonField Systems Vium Inc.VACCINESJN Medical Corp.Universal Stabilization Technologies, Inc.Vaxess Technologies

2017 PARTICIPATING INVESTORS

8

INVESTORS5AM VenturesA C Binder CorpAbbVie Inc.AcerasAceras Life SciencesAceras PartnersACS Investment PartnersACT Capital Management Acuris PartnersAegis CapitalAisling Capital LLCAkemi CapitalALEPH CAPITALAlignment Ventures, LLCAmzak HealthAnson Funds Arch Venture PartnersArcus VenturesAriel InvestmentsAristar CapitalAsahi Kasei America, Inc.Ashford Capital ManagementAspire Capital PartnersAstellas Venture Management LLCATEL VenturesAthena Bio VenturesAtheneos CapitalAthyrium Capital ManagementAtlantic Capital GroupAtlas VentureAuxol CapitalAWM Investment CoBaird CapitalBank of America/Merrill LynchBarclaysBarracuda Finance LLCBearing Circle CapitalBioMed VenturesBiondo Investment AdvisorsBiotech Investment GroupBioVenture PartnersBishop Capital ManagementBMO CapitalBrean CapitalBridegBioBrio CapitalBTIGCabot Capital Group CAM CapitalCanaccord GenuityCantor FitzgeraldCapital Family OfficeCapital Midwest FundCato BioVenturesCedrus InvestmentsChardan Capital MarketsChurch Pension FundCowenCrede Capital GroupCrosby AdvisorsCrown Point GroupDabar Investment AssociatesDaniloff CapitalData Collective

Deca Ventures, LLCDeepStream Global ManagementDeerfield ManagementDelphi Ventures Delwar Capital Management LLCDiscover FundDolphin Asset Management Domain AssociatesDynamk CapitalE Squared CapitalEagle Asset ManagementEaston CapitalEdgewood Management LLCEGB Advisors PR LLCEleven BiotherapeuticsEmerald AdvisersEnso VenturesESC AdvisorsEversept Partnersexcelyrate CapitalFaridanFBR & Co.FC Capital ManagementFederated Kaufmann FundFirst Island CapitalFive Prime Advisors LLCFletcher Spaght VenturesFMB Research Inc.Fosun Pharma Group-WanbangFountain Healthcare PartnersF-Prime Capital PartnersFranklin TempletonFundRxGCF Family OfficeGC FinanceGenesys Capital PartnersGenScriptGlobal Asset AdvisorsGMX Capital PartnersGoldwaterGood Health CapitalGradus/RSJ Life SciencesGriffin SecuritiesHayfin Capital Management H.C. Wainwright & Co.HealthCare Royalty PartnersHealthcare Value Capital, LLCHelix Management, IncHercules CapitalHI Investors CapitalH.I.G. CapitalHorizon Technology FinanceHorton Point LLCHudson Bay CapitalHumanwell Healthcare GroupIgnite CapitalIllumina VenturesInnoviva, Inc.International Finance CorporationInventis Investment Holdings (China) LtdiNVENTRAM INC.IRC Securities/Strategy SignalIron Wolf AdvisorsJanney Montgomery ScottJefferies

INVESTOR REGISTRATION UP MORE THAN

30% OVER 2016.

bio.org/CEO

9#BIOCEO17

CEO INVESTORCONFERENCE

JEG Capital Partners LLCJH Darbie & CoJina Ventures Inc.JMP SecuritiesJohnson & Johnson Innovation - JJDC IncJohnston AssociatesJonesTradingJP Morgan SecuritiesKalka FundKatalyst Securities LLCKatz AssociatesKCMKESA PartnersL1 Capital GlobalLadenburg Thalmann & Co.Laidlaw & CompanyLF Advisors LLCLeerinkLeonite CapitalLifeScience EquityPartners, LLCLifeTech CapitalLincoln Financial AdisorsLincoln Park CapitalLittle gem life sciences fundLivingston LLCLoeb PartnersLoncar InvestmentsLongitude CapitalLPL FinancialLSWORKSMadison Square Capital LLCMagid Family OfficeMagnaMarathon Asset ManagementMaxim GroupMayfair Capital Partners LLCMaz Capital Advisors LLCMedex CapitalMediqventuresMerckMid Atlantic Bio AngelsMilestone CapitalMorgan StanleyMorgens, Waterfall, Vintiaidus & Company,

Inc.Mossrock Capital, LLCMountain Brook CapitalMount Sinai Investment FundMP Healthcare VentureM&T Global Partners MTS Health InvestorsMVM Life Science PartnersMVP Capital PartnersNational Securities CorporationNEANeedham & Co.New Frontier Capital, LPNexus LSPNJ Investment DivisionNoble EquityNoble Life Science PartnersNomura InstinetNomura Securities InternationalNordcon CapitalNorgine Ventures

NovaQuest CapitalNovatio VenturesNovo NordiskNSIP LLCNYS Innovation Venture Capital FundOak Ridge Investments LLCOberland CapitalOechsle International AdvisorsOlayan America CorpOpaleyeOppenheimer & CoOpus Point PartnersOrbiMedOrchard View Capital Advisors LPOxford FinancePalo Alto InvestorsPappas VenturesPARK AVE CAPITAL MGMT INTL.Parkfield Funding, LLCParkville AdvisorsPark York LLCPeter B. Cannell & Co.Petrus Capital HoldingsPfizer IncPipeline CapitalPiper JaffrayPortola Captial PartnersPrevail Partners LLCPrinceton BioPharma Capital Partners,

LLCPrinceton Portfolio Strategies Group, LLCPrism Biomedical ResearchQilu BioVentures Fund QVT FinancialRainbow Bridge Advisors Raymond JamesRBC Capital MarketsRelativity Healthcare PartnersRemiges VenturesRevach Fund LPRidgeback Capital ManagementRoosevelt InvestmentsROTH Capital PartnersRuddigore PartnersS&P Capital IQSachs Investment GroupSanten IncSBIC ProgramSBP ManagementSC Fundamental, LLCSchroder Investment ManagementSeaside88Second Line CapitalSector Asset ManagementSerrado CapitalSilicon Valley BankSilverarc Capital, LLCSilverarrowpartnersSimRx advisorsSio Capital ManagementSkolkovo BiofundSlater Technology FundSofinnova VenturesSolar Capital PartnersSource Capital Group

Stadnyk and Partners Family OfficeStanphyl CapitalSternAegis VenturesStifelSunTrust Robinson HumphreySurveyor Capital (Citadel LLC)SV Life Sciences Managers LLPSymphony Capital LLCSyno CapitalTaiAn Technologies/Eminent VCTang Capital ManagementTanaka Capital ManagementThe Astrologers Fund, IncThe HF Group, LLCTriPoint Global EquitiesTryphon Capital AdvisorsTS Family of FundsTurret Capital MangementV2M CapitalValquest Capital ManagementVector Capital LtdVector Resource FundsVersant VenturesViriathus Holdings LLXVirtus Inspire VenturesVista Point CapitalWallachBeth CapitalWBB Securities LLCWellington FinancialWestPark CapitalWilliam BlairWolf Capital ManagementWolfswood PartnersXeraya Capital

bio.org/CEO10

BIO’s One-on-One Partnering™ system is the interactive environment that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide.

Using the system, companies are able to:m Pre-schedule 30-minute private 1x1 meetings

m Source potential collaborations and funding opportunities with an international audience

m Communicate directly with prospective investors and C-level executives in biotech and pharma

m Search company and investor profiles for potential business partnerships

BIO ONE-ON-ONE PARTNERING MEETINGS

AUDIENCE DEMOGRAPHICS

86%86% of attendees are VP or C-Level

DirectorOther VPC-level

86%

4% 10% 76% 10%

Breakdown by Therapeutic Focus:

Job Profile:

Companies Profile:

82%82% of all companies attending are biopharma

Attendees: 1,400+BIO One-on-One Partnering Meetings: 2,500+Registered Investors: 650Company Presentations: 190Expert Speakers: 58

< $50M: 36%

$500M: 4%

$100M-250M: 32%

$50M-100M: 22%

$250M-500M: 6%

Breakdown by Market Cap:Oncology: 29%

Platform Discovery: 2%

Infectious Diseases: 2%

CNS: 13%

Other: 10%Orphan/Rare Diseases: 10%

Autoimmune Inflammation: 7%

Devices & Drug Delivery: 4%

Metabolic Diseases: 4%

Ophthalmology: 4%

Multiple: 4%

Regenerative Medicine: 3%

Cardiovascular: 3%

Gastrointestinal: 3%

Diagnostics: 2%

10#BIOCEO17

SCHEDULED MEETINGS

UP 20%

11#BIOCEO17

CEO INVESTORCONFERENCE

11#BIOCEO17

SPONSORSLOCAL CO-HOST

usedlabequipment.com

SUPPORTING BANK SPONSORS

DOUBLE HELIX SPONSORS

CONFERENCE SPONSORS

MEDIA PARTNERS

REGIONAL PARTNERS

HELIX SPONSOR

TM

bio.org/CEO12 bio.org/CEO12

February 13-14, 2017 • The Waldorf Astoria New York

ADVISORY COMMITTEE

John ChambersPresident and Head of Healthcare Investment Banking, H.C. Wainwright & Co. LLC

Barbara J. Dalton, PhD Vice President, Venture Capital, Pfizer Inc.

Linda S. Grais, MDPresident and Chief Executive Officer, Ocera Therapeutics, Inc.

Mike KingManaging Director and Senior Biotech Analyst, JMP Securities

Jonathan LeffPartner, Deerfield Management; Chairman, Deerfield Institute

Michael Margolis, RPhManaging Director and Head of Healthcare Investment Banking, ROTH Capital Partners

Jason ParkPrincipal, Flagship Ventures

Susan Peschin, MHSPresident and CEO, Alliance for Aging Research

Dennis J. PurcellFounder and Senior Advisor, Aisling Capital

Stephen SandsVice Chairman Investment Banking and Chairman Global Healthcare Group, Lazard

Rajeev ShahManaging Director and Portfolio Manager, RA Capital Management

Nathan Tinker, PhDExecutive Director, New York BIO

Brian HagertySenior Director, Head of Healthcare Capital Markets, New York Stock Exchange

Michael MirskyManaging Director, Investment Banking, H.C. Wainwright & Co., LLC

Carlo Rizzuto, PhDPartner, Versant Ventures

Matthew Roden, PhDVice President and Head of Strategic Corporate Development, Bristol-Myers Squibb

Nouhad HusseiniVice President, Business Development, Regeneron Pharmaceuticals, Inc.

Timothy P. O’Connor, PhDExecutive Vice President, The Rockefeller University

HOSTED BY: